Mandelbaum Barrett PC’s Cannabis, Hemp and Psychedelics Practice continues to lead the national dialogue as federal policymakers move toward a new ban on hemp-derived products.
In a new Forbes article, Joshua S. Bauchner, Chair of the Practice Group, warns that Congress’s last-minute decision to re-criminalize hemp-derived THC would destabilize a “robust, growing, billion-dollar industry employing hundreds of thousands.” He cautions that the proposal reinforces a “false duality” between hemp and cannabis — a distinction Congress itself created — and risks wiping out access to crucial full-spectrum products relied on by vulnerable patients.
As competing industry interests intensify and the regulatory future of hemp hangs in the balance, Josh continues to provide critical perspective on the policy decisions shaping access, safety, and the broader cannabis marketplace.
Read the full Forbes article here.